China Resources Sanjiu Medical & Pharmaceutical (SHE:000999) recorded a 7.9% decline in attributable profit for the first half of 2026 to 1.67 billion yuan from 1.82 billion yuan a year prior.
Basic EPS fell to 1 yuan from 1.09 yuan in the corresponding period of the previous fiscal year, according to a Tuesday filing by parent China Resources Pharmaceutical (HKG:3320).
The pharmaceutical company's operating revenue increased 1.4% to 15 billion yuan from 14.8 billion yuan previously.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments